8-K: Merck Completes Acquisition of Terns Pharmaceuticals

Merck has successfully acquired Terns Pharmaceuticals in a tender offer and subsequent merger, with Terns now operating as a wholly owned subsidiary.

Summary

• Terns Pharmaceuticals, Inc. has been acquired by Merck Sharp & Dohme LLC (Merck) through a tender offer and a subsequent merger.
• The tender offer, which commenced on April 7, 2026, at a price of $53.00 per share, concluded on May 4, 2026.
• Approximately 86.36% of Terns' outstanding shares were tendered and accepted for purchase.
• The merger was completed on May 5, 2026, making Terns a wholly owned subsidiary of Merck.
• All outstanding Terns stock options and restricted stock units were cancelled and converted into cash payments based on the merger consideration.
• Terns' common stock will be delisted from the Nasdaq Global Select Market, and its reporting obligations will be terminated.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Terns shareholders due to the successful acquisition at a premium, but neutral for the market as it represents consolidation rather than new growth.

Positives

• Successful completion of the acquisition by Merck, providing a clear exit for Terns shareholders at a premium price of $53.00 per share.
• High tender participation rate of 86.36% indicates strong shareholder acceptance of the offer.
• Merger completed without a shareholder vote, streamlining the acquisition process.
• All outstanding equity awards were converted into cash payments, providing immediate value to option and RSU holders.

Negatives

• Terns Pharmaceuticals ceases to exist as an independent publicly traded entity.
• The delisting from Nasdaq signifies the end of Terns' public trading history.

Risks

• Potential for integration challenges as Terns is absorbed into Merck's operations.
• Uncertainty regarding the future development and commercialization of Terns' pipeline assets under Merck's management.

Future Outlook

The future outlook for Terns' assets and pipeline is now determined by Merck's strategic decisions following the acquisition.

Management Comments

• The filing details the completion of the acquisition and merger, with Terns becoming a wholly owned subsidiary of Merck.
• Information regarding new directors and officers of the surviving corporation is provided.

Industry Context

StockSavvy.ai notes that this acquisition by Merck, a major pharmaceutical player, highlights the ongoing trend of consolidation within the biopharmaceutical industry, driven by the pursuit of innovative pipelines and technologies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $53.00 per share in cash, providing a profitable exit.
• Option and RSU Holders: Received cash payments for their awards.
• Employees: Potential for changes in roles, responsibilities, and benefits as Terns integrates into Merck.
• Creditors: Terms of existing debt may be affected by the change in ownership; however, the filing does not detail specific impacts.

Next Steps

• Delisting of Terns Pharmaceuticals' common stock from the Nasdaq Global Select Market.
• Termination of Terns' registration and reporting obligations with the SEC.
• Integration of Terns' assets and personnel into Merck's operations.

Key Dates

Keywords

Merger, Acquisition, Tender Offer, Terns Pharmaceuticals, Merck, Nasdaq Delisting, SEC Filing, Form 8-K